Anne A. Finucane - 14 May 2026 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Reporting relationship: Director
Issuer ticker: CVS
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 May 2026, 17:08:43 UTC
Prior SEC filing: 03 Feb 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Anne M. Finucane

Key filing fact

Anne A. Finucane filed Form 4 for CVS HEALTH Corp (CVS) on 15 May 2026.

Key facts

This page summarizes Anne A. Finucane's Form 4 filing for CVS HEALTH Corp (CVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 May 2026, 17:08.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001511491 Primary reporting owner

Finucane Anne A.

Relationship: Director
Address: ONE CVS DRIVE, WOONSOCKET
Signature: /s/ Anne M. Finucane
Signature date: 15 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVS transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +1,544
Change %: +9.2%
Price: $97.15^*
Shares after: 18,355
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,544
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

Footnote F2

Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.